Anthropic's Wet Lab Push: AI-Guided Biology Beyond Drug Discovery

Anthropic Quietly Sets Up Wet Lab for AI-Driven Biology

According to a Reuters report, Anthropic has quietly built a wet laboratory in the San Francisco Bay Area to conduct physical biology work that goes beyond computer simulation. Two sources familiar with the matter say the company is attempting to have AI systems such as Claude participate in experiment execution, and it has designated life sciences as a key investment area. Anthropic has not publicly disclosed specific research projects or interim results.

Lab Not Solely for Drug Discovery

Anthropic's life sciences lead, Eric Kauderer-Abrams, confirmed the existence of the wet lab in an interview with Reuters. He stated that the ultimate validation of biological research still occurs in real laboratories and will continue to do so for the foreseeable future. Anthropic currently operates similarly to most biotech companies: some work is done in-house, while other parts are outsourced to external partners.

A company spokesperson subsequently clarified that the existing lab is not specifically for drug discovery ; its exact purposes remain undisclosed. In June, Anthropic indicated plans to conduct preclinical research in areas where traditional companies lack economic incentives and to explore treatments for rare diseases. This path remains early: moving a candidate molecule from lab to market typically takes years, requires passing clinical safety and efficacy tests, and most drug projects ultimately fail. Anthropic is not currently running clinical trials.

For CEO Dario Amodei, the work has personal motivation; he has written that his father died a few years before a treatment for his disease became available. Kauderer-Abrams said that using powerful AI to advance life sciences represents one of the biggest opportunities in Anthropic's mission to "benefit humanity."

Safety Controversies and Life Sciences Ambitions

Like other biotech firms, Anthropic is exploring physical automation. Sources say the company wants Claude to direct robots to carry out experiments, reducing human intervention. A spokesperson emphasized that human oversight and participation remain a safety prerequisite.

Kauderer-Abrams described the field as "very early" but with potential to accelerate many scientific processes. In August, Anthropic released the Model Hardware Standard to help AI systems connect to and operate laboratory equipment; the academic project PyLabRobot also targets lab automation.

Amid the automation push, Anthropic faces intensifying AI safety debates. Over the past two weeks, some researchers have warned that AI could lead to human extinction. Anthropic also disclosed that it had discovered usage patterns in its systems that could be exploited for biological weapons development, a claim that drew skepticism. Amodei has called for slowing development and warned that more capable AI could cause catastrophic outcomes. Meanwhile, Anthropic is reportedly preparing an IPO that could value the company at up to $2 trillion to secure more R&D funding.

Kauderer-Abrams said the company's life sciences work must constantly balance accelerating R&D with controlling risk. Anthropic aims to improve its models' ability to support drug development while carefully setting deployment boundaries.

Life Sciences Now One of Anthropic's Largest Investment Areas

Anthropic unveiled its life sciences strategy at a June event, launched Claude Science , and added Novartis CEO Vas Narasimhan to its board. The company also confirmed the acquisition of startup Coefficient Bio ; media reports put the deal at roughly $400 million paid in stock, though Anthropic declined to comment on the amount.

The company is expanding internal lab investment. Kauderer-Abrams noted that owned facilities allow some work to be completed faster and help the company accumulate firsthand biology experience; steps suited for outsourcing will still go to external partners. Job postings show Anthropic is hiring a procurement and operations lead as well as talent in protein and nucleic acid characterization; one description states the goal is to accelerate life sciences progress by an order of magnitude. Kauderer-Abrams affirmed that life sciences is already one of Anthropic's largest areas in terms of personnel and resources.

Targeting "Undruggable" Diseases, Facing Trust and Clinical Hurdles

Kauderer-Abrams believes AI has an opportunity to advance R&D for "undruggable" diseases. The company's technical directions include bispecific and trispecific antibodies that can act on multiple targets simultaneously, which present high design and validation difficulty.

Anthropic has not disclosed specific disease targets or project progress. Finding a candidate molecule is only the starting point; subsequent animal studies, clinical trials, and regulatory review are required. Alphabet's Isomorphic Labs has invested years in drug discovery, with its clinical entry delayed to late 2026.

Anthropic currently provides model standards, AI services, and tools to pharmaceutical companies including Roche's Genentech, Bristol Myers Squibb, and Novo Nordisk. These partnerships raise data and competition concerns: clients may worry that Anthropic could gain competitively useful information from different drug projects, although the company says it isolates client data.

Kauderer-Abrams stated that Anthropic is not conducting clinical trials, focuses on long-neglected needs, and does not directly compete with pharma and biotech companies whose core business is bringing drugs to market. For Anthropic, the wet lab is a new foothold for AI in life sciences; whether it can translate its experimental automation advantage into verifiable, marketable treatments will depend on future data and clinical results.

Reference: https://www.reuters.com/world/anthropic-quietly-sets-up-biology-lab-it-ramps-ai-drug-program-2026-09-18/